Citi analyst Samantha Semenkow raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $25 and keeps a Buy rating on the shares following the fiscal Q2 report. The company will now present data from both batoclimab Phase 3 thyroid eye disease trials in 2026, the analyst tells investors in a research note. Citi sees Roivant’s investor day on December 11 laying a catalyst path for the shares in 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV: